Journal Article

Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?

Iain C. Macdougall

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 20, issue suppl_8, pages viii18-viii21
Published in print September 2005 | ISSN: 0931-0509
Published online September 2005 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfh1112
Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?

Show Summary Details

Preview

After 1998, the number of reported cases of pure red cell aplasia (PRCA) increased dramatically among patients with chronic renal failure treated with exogenous erythropoietin, although the incidence of this condition has now abated. Antibody-positive PRCA has been most commonly associated with use of the Eprex® brand of epoetin-α. ESA (erythropoiesis-stimulating agent)-associated PRCA remains rare, and suspected cases should undergo a thorough diagnostic work-up before laboratory testing for anti-ESA antibody-positive status. This article provides an overview of the recent history and growing understanding of ESA-associated PRCA together with current approaches to the management of this rare side effect of an otherwise valuable therapy.

Keywords: anaemia; chronic renal failure; erythropoiesis-stimulating agent (ESA); immunogenicity; PRCA (pure red cell aplasia)

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.